BSI-401: Follow-on PARP Inhibitor (Oral)
BSI-401 is our follow-on Poly (ADP-ribose) polymerase (PARP) inhibitor candidate. We are currently investigating it as a potential oral therapy in preclinical models of pancreatic cancer through a sponsored research program at the University of Texas, M.D. Anderson Cancer Center.
Learn more about the candidates in our PARP Inhibitor Program:
Learn more about our BSI-301: Preclinical Stage Iodothyronine Anti-tubulin Program.